Articles tagged "Induction therapy"

2020 American Transplant Congress
Pediatric Primary Kidney Transplant Recipients Outcomes by Immunosuppression Induction Received in the United States
S. M. Riad¹, S. Jackson², A. Matas³, S. Chinnakotla³, P. Verghese⁴
¹University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, Fairview Health Services, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN, ⁴Pediatrics, University of Minnesota, Minneapolis, MN
*Purpose: Induction immunosuppression types for pediatric transplant recipients vary widely by transplant centers. We sought to study the impact of different induction types on recipients…
2020 American Transplant Congress
Basiliximab vs Antithymocyte Globulin Induction with Early Steroid Withdrawal in Kidney Transplant Recipients: Early Rejection Outcomes
A. Szczepanik¹, C. Burrelli¹, A. Bixby¹, K. Yadav², K. Chavin²
¹Pharmacy, University Hospital Cleveland Medical Center, Cleveland, OH, ²Surgery, University Hospital Cleveland Medical Center, Cleveland, OH
*Purpose: Steroid withdrawal within the first month of kidney transplant (KT) remains controversial and has demonstrated a higher risk of acute rejection. The impact of…
2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
R. M. Hofmann¹, J. Combs², K. J. Schmidt³, T. Dyckman⁴
¹Nephrology, Renal Associates of West Michigan, Grand Rapids, MI, ²Pharmacy/Transplant, Mercy Health St. Mary's, Grand Rapids, MI, ³Pharmacy, Ferris State University College of Pharmacy, Big Rapids, MI, ⁴Pharmacy, Mercy Health St. Mary's, Grand Rapids, MI
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…
2020 American Transplant Congress
Depletional Induction Improves Kidney Graft and Patient Survival in Recipients with a Previous Liver Transplant in the United States
S. M. Riad¹, N. Lim¹, S. Jackson², A. Matas³, J. Lake¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Fairview Health Services, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Induction choices for kidney-after-liver transplant recipients are variable. We examined the impact of kidney induction types on kidney graft and patient survival in liver…
2020 American Transplant Congress
Differences in Alemtuzumab Dosing Does Not Affect Early Kidney Transplant Outcomes
A. Pressley, R. Stratta, J. Rogers, A. Farney, G. Orlando, W. Doares, A. Reeves-Daniel, C. Jay
Wake Forest Baptist Health, Winston-Salem, NC
*Purpose: Alemtuzumab (Alem) is a widely used medication for induction therapy in kidney transplantation. However, there is limited evidence comparing outcomes with low versus high…
2020 American Transplant Congress
Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients
K. Soliman¹, H. Ali², T. Fulop¹, A. Osman³, A. Halawa⁴
¹Medicine, Medical University of South Carolina, Charleston, SC, ²Medicine, Royal Stoke, Royal Stoke, United Kingdom, ³Medicine, Cairo University, Cairo, Egypt, ⁴Medicine, University of Liverpool, Liverpool, United Kingdom
*Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…
2020 American Transplant Congress
Maintenance Steroids in the Setting of Alemtuzumab Induction Post-Kidney Transplant Increases Risk of Infection and Hospital Readmission
A. R. Webb, A. A. Al-Bahou, A. J. Brueckner, A. T. Logan, R. S. Baliga, L. J. Bowman Anger
Tampa General Hospital, Tampa, FL
*Purpose: This study sought to assess the safety of steroid-containing maintenance immunosuppression in the setting of alemtuzumab (ALEM) induction.*Methods: Adult (>18 years) kidney transplant recipients…
2020 American Transplant Congress
Thymoglobulin Induction in Kidney Transplant Recipients: A Single Center Experience Comparing 3 Mg/kg vs 5 Mg/kg Cumulative Dosing
K. Progar¹, S. January¹, N. Nesselhauf¹, J. Hagopian¹, A. Malone²
¹Transplant, Barnes-Jewish Hospital, St. Louis, MO, ²Transplant Nephrology, Washington University, St. Louis, MO
*Purpose: Beginning in 2016, our center implemented a protocol change to thymoglobulin (r-ATG) induction dosing in kidney transplant recipients at low rejection risk from 5…
2020 American Transplant Congress
Single Center Experience Using Low-Dose Antithymocycte Globulin for Induction Following Heart Transplant
T. J. ONeill IV, G. Jao, A. Kelkar, B. Pisani
Wake Forest Baptist Health System, Winston Salem, NC
*Purpose: The use of induction therapy after cardiac transplantation remains highly variable, not only in terms of which agent is used, but whether it is…
2020 American Transplant Congress
Navigating Through IgM Antibodies in Deceased Donor Kidney Transplants from A2/A2B Donors to B Recipients
M. Kueht, A. Gamilla-Crudo, S. Hussain, R. Kulkarni, J. Fair, H. Stevenson-Lerner, M. Mujtaba
University of Texas Medical Branch, Galveston, TX
*Purpose: Multiple studies have shown acceptable deceased donor transplant (DDT) outcomes from A2 and A2B donors into B recipients; however, concerns remain for acute rejection…

« Previous Page
1
…
6
7
8
9
10
…
31
Next Page »